Tale Of Science Rivalry Marks Chemist's Debut As Novelist

This is not science fiction, but “science in fiction,” says Carl Djerassi, the celebrated Stanford chemist whose first novel, Cantor’s Dilemma, is being published this month by Doubleday. The novel portrays what Djerassi calls “the soul and baggage of contemporary science,” including its brutal competition, baroque professional etiquette, and complicated relations between professors and their students. Nearly all its science is real; also, real-life scientists and

Written byCarl Djerassi
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

This is not science fiction, but “science in fiction,” says Carl Djerassi, the celebrated Stanford chemist whose first novel, Cantor’s Dilemma, is being published this month by Doubleday. The novel portrays what Djerassi calls “the soul and baggage of contemporary science,” including its brutal competition, baroque professional etiquette, and complicated relations between professors and their students. Nearly all its science is real; also, real-life scientists and their work appear in context. Cantor’s Dilemma focuses on the issue of scientific fraud, which, Djerassi demonstrates, is often not a case of black and white, but a gray and misted region full of pitfalls for the easy moralist.

Djerassi’s protagonist, I. Cantor, is a highly respected cell biologist at a university in the Midwest. In these excerpts, Djerassi describes how Cantor pushes his brilliant postdoc Jerry Stafford for experimental verification of Cantor’s radical newthe- ory of tumori genesis—a theory that, the professor knows, ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies